These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7473547)

  • 1. Piperazinylalkyl heterocycles as potential antipsychotic agents.
    Scott MK; Baxter EW; Bennett DJ; Boyd RE; Blum PS; Codd EE; Kukla MJ; Malloy E; Maryanoff BE; Maryanoff CA
    J Med Chem; 1995 Oct; 38(21):4198-210. PubMed ID: 7473547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-aryl-N'-benzylpiperazines as potential antipsychotic agents.
    Reitz AB; Baxter EW; Bennett DJ; Codd EE; Jordan AD; Malloy EA; Maryanoff BE; McDonnell ME; Ortegon ME; Renzi MJ
    J Med Chem; 1995 Oct; 38(21):4211-22. PubMed ID: 7473548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
    Reitz AB; Baxter EW; Codd EE; Davis CB; Jordan AD; Maryanoff BE; Maryanoff CA; McDonnell ME; Powell ET; Renzi MJ; Schott MR; Scott MK; Shank RP; Vaught JL
    J Med Chem; 1998 Jun; 41(12):1997-2009. PubMed ID: 9622541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrole mannich bases as potential antipsychotic agents.
    Scott MK; Martin GE; DiStefano DL; Fedde CL; Kukla MJ; Barrett DL; Baldy WJ; Elgin RJ; Kesslick JM; Mathiasen JR
    J Med Chem; 1992 Feb; 35(3):552-8. PubMed ID: 1346653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
    López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
    J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Block of conditioned avoidance responding in the rat by substituted phenylpiperazines.
    Martin GE; Elgin RJ; Kesslick JM; Baldy WJ; Mathiasen JR; Shank RP; Scott MK
    Eur J Pharmacol; 1988 Nov; 156(2):223-9. PubMed ID: 3240768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
    Abou-Gharbia M; Patel UR; Webb MB; Moyer JA; Andree TH; Muth EA
    J Med Chem; 1988 Jul; 31(7):1382-92. PubMed ID: 2898533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
    Martin GE; Elgin RJ; Mathiasen JR; Davis CB; Kesslick JM; Baldy WJ; Shank RP; DiStefano DL; Fedde CL; Scott MK
    J Med Chem; 1989 May; 32(5):1052-6. PubMed ID: 2565400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.
    Bøgesø KP; Arnt J; Frederiksen K; Hansen HO; Hyttel J; Pedersen H
    J Med Chem; 1995 Oct; 38(22):4380-92. PubMed ID: 7473566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vivo effects of the 1,2,4-piperazine derivatives MM5 and MC1, putative 5-HT agonists, on dopamine and serotonin release in rat prefrontal cortex.
    Iskra-Jopa J; Gołembiowska K; Dziubina A; Cybulski M; Duszyńska B; Chilmonczyk Z
    J Pharm Pharmacol; 2005 Feb; 57(2):205-11. PubMed ID: 15720784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics.
    Taverne T; Diouf O; Depreux P; Poupaert JH; Lesieur D; Guardiola-Lemaître B; Renard P; Rettori MC; Caignard DH; Pfeiffer B
    J Med Chem; 1998 Jun; 41(12):2010-8. PubMed ID: 9622542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
    Norman MH; Rigdon GC; Navas F; Cooper BR
    J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
    Wustrow D; Belliotti T; Glase S; Kesten SR; Johnson D; Colbry N; Rubin R; Blackburn A; Akunne H; Corbin A; Davis MD; Georgic L; Whetzel S; Zoski K; Heffner T; Pugsley T; Wise L
    J Med Chem; 1998 Feb; 41(5):760-71. PubMed ID: 9513604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
    Yevich JP; New JS; Lobeck WG; Dextraze P; Bernstein E; Taylor DP; Yocca FD; Eison MS; Temple DL
    J Med Chem; 1992 Nov; 35(24):4516-25. PubMed ID: 1361578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the halogen bonding on D
    Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
    Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thieno[3,2-c]pyridine and furo[3,2-c]pyridine rings: new pharmacophores with potential antipsychotic activity.
    New JS; Christopher WL; Yevich JP; Butler R; Schlemmer RF; VanderMaelen CP; Cipollina JA
    J Med Chem; 1989 Jun; 32(6):1147-56. PubMed ID: 2542551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
    Norman MH; Rigdon GC; Hall WR; Navas F
    J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.